- POSITIVE
Quarterly Revenue Senores Pharmaceuticals Sep-2026 Quarterly Revenue is Rs 50 Cr which is growth of 8.0% YoY.
- POSITIVE
Quarterly Net Profit Senores Pharmaceuticals Sep-2026 Quarterly Net Profit is Rs 8 Cr which is growth of 20.1% YoY.
NSE: SENORES | BSE: 544319
Senores Pharmaceuticals Live Share Price Today, Share Analysis and Chart
aboutSenores Pharmaceuticals Limited is a research-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex pharmaceutical products. The company focuses on specialty and underpenetrated therapeuti... Read More
1111.00-22.90(-2.02%)
537.1K
NSE+BSE Volume
NSE 02 Nov, 2026 3:29 PM (IST)
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Please subscribe to view forecaster data
Senores Pharmaceuticals Stock Price Analysis
Day Price Range-2.0% 1 Day return | 1111 (LTP) 1,093.51,152 LowHigh |
|---|---|
Week Price Range-8.6% 1 Week return | 1111 (LTP) 1,053.41,341 LowHigh |
Month Price Range-17.7% 1 Month return | 1111 (LTP) 1,053.41,424 LowHigh |
52 Week Price Range44.1% 1 Year return | 1111 (LTP) 7061,599 LowHigh |
Senores Pharmaceuticals Forecaster - Analyst Share Price Target and Estimates
Revenue forecast
EPS forecast
CURRENT EPS
AVG. ESTIMATE
Consensus Recommendation
5 ANALYST Recommendations
STRONG BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Forecaster
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Senores Pharmaceuticals quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.4 | 36.5 | 59 | 38.5 | 46.7 | 28.2 | 21.1 | 16.8 | 12.7 | 9.9 | 40.9 | 11.1 | ||
Operating Exp. | 34.6 | 29.3 | 40.3 | 29.7 | 33.8 | 21 | 14.6 | 12 | 11 | 8.3 | 34.1 | 9.4 | |
Operating Profit | 1.1 | -2.3 | -3.5 | -0.9 | 1.5 | -1.2 | -2.7 | -2.4 | -1.3 | -0.8 | -0.1 | -0.5 | |
Operating Profit Margin % | 2.97% | -8.63% | -9.45% | -3.23% | 4.30% | -5.80% | -23.10% | -25.23% | -13.91% | -10.29% | -0.18% | -5.95% | |
Depr. | 3.9 | 3.6 | 4.1 | 3.6 | 3.7 | 1.9 | 1.3 | 0.8 | 0.5 | 0.5 | 2 | 0.5 | |
Interest | 2.2 | 2.2 | 1.9 | 1.8 | 1.6 | 1.8 | 2.4 | 2.7 | 0.7 | 0.8 | 2.7 | 0.7 | |
Profit Before Tax | 9.7 | 1.4 | 12.7 | 3.5 | 7.7 | 3.6 | 2.9 | 1.3 | 0.5 | 0.4 | 2 | 0.5 | |
Tax | 2 | 0.4 | 4.2 | 0.9 | 1.2 | 0.9 | 0.9 | 0.3 | 0.2 | 0.1 | 1.2 | 0.3 | |
Net Profit | 7.7 | 1 | 8.5 | 2.7 | 6.4 | 2.7 | 2 | 1.1 | 0.3 | 0.3 | 0.8 | 0.2 | |
EPS Adj. latest | 1.7 | 0.2 | 1.8 | 0.6 | 1.4 | 0.6 | 0.4 | 0.2 | 0.1 | 0.1 | 0.2 | 0 | |
Net profit TTM | 19.9 | 18.6 | 20.3 | 13.8 | 12.2 | 6.1 | 3.7 | 2.5 | 1.6 | - | - | - | |
Basic EPS TTM | 4.3 | 4 | 4.4 | 3 | 2.7 | 1.3 | 0.8 | 0.5 | 0.5 | - | - | - | |
Earnings Transcripts | |||||||||||||
AI Summary | |||||||||||||
Results PDF | |||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Senores Pharmaceuticals Technical Analysis
Senores Pharmaceuticals EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 1219.2 |
|---|---|
| 10 Day | 1244.6 |
| 12 Day | 1252.5 |
| 20 Day | 1280.3 |
| 26 Day | 1297.2 |
|---|---|
| 50 Day | 1330.3 |
| 100 Day | 1296.4 |
| 200 Day | 1161.9 |
Senores Pharmaceuticals Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202633.5%
Week35.0%
Month40.6%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Senores Pharmaceuticals Resistance and Support
1138.43
Pivot
| First Resistance | 1223.5 |
|---|---|
| Second Resistance | 1313.0 |
| Third Resistance | 1398.1 |
| First Support | 1048.9 |
|---|---|
| Second Support | 963.8 |
| Third Support | 874.3 |
| Day RSI | 33.3 |
|---|---|
| Day MACD | -44.7 |
| Day MFI | 18 |
| Day MACD Signal Line | -39.3 |
Senores Pharmaceuticals Beta
| 1 Month | 0.8 |
|---|---|
| 1 Year | 0.9 |
| 3 Month | 0.6 |
|---|---|
| 3 Year | - |
Senores Pharmaceuticals Price Change Analysis
↓-17.7%
Over 1 Month
LowHigh
1053.41424
↓-14.9%
Over 3 Months
LowHigh
1053.41599
↑23.6%
Over 6 Months
LowHigh
877.61599
↑44.1%
Over 1 Year
LowHigh
7061599
Senores Pharmaceuticals Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| ASTORNE CAPITAL VCC ARVEN | Bulk | Sell | 24 Dec 2025 | 792.12 | 500,000 | NSE |
| YASHKUMAR SHANTILAL SANGHVI | Bulk | Sell | 24 Dec 2025 | 792 | 276,270 | BSE |
| RAVI PAWANKUMAR SANGHVI | Bulk | Sell | 24 Dec 2025 | 792.19 | 292,500 | BSE |
| HRTI PRIVATE LIMITED | Bulk | Sell | 29 Jul 2025 | 688.87 | 237,321 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 29 Jul 2025 | 689.98 | 316,091 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Purchase | 29 Jul 2025 | 689.33 | 316,091 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Purchase | 29 Jul 2025 | 686.66 | 269,264 | NSE |
| QE SECURITIES LLP | Bulk | Sell | 24 Jul 2025 | 684.18 | 247,903 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 24 Jul 2025 | 685.44 | 639,285 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Purchase | 24 Jul 2025 | 684.96 | 639,285 | NSE |
Senores Pharmaceuticals Corporate Actions
Senores Pharmaceuticals Board Meetings
Senores Pharmaceuticals past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
129 Oct 2026 | Quarterly Results | - |
227 Jul 2026 | Quarterly Results | - |
314 May 2026 | Audited Results | - |
420 Jan 2026 | Quarterly Results & Others | To consider other business matters. |
507 Jan 2026 | Others | Inter alia, 1. To consider and evaluate proposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group. |
Senores Pharmaceuticals Research Reports
Senores Pharmaceuticals research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 114 May 2026 | BOB Capital Markets Ltd. Target | 1250 | 1050.35 | Buy | 19.01% | 5.77% | |
| 219 Jan 2026 | BOB Capital Markets Ltd. Target | 1108 | 784.55 | Buy | 41.23% | 41.61% | |
| 306 Nov 2025 | BOB Capital Markets Ltd. Target | 1006 | 822.95 | Buy | 22.24% | 35% | |
| 421 Aug 2025 | BOB Capital Markets Ltd. | 850 | 724.25 | Buy | 17.36% | 53.4% | |
| 518 Dec 2024 | SBI Securities | - | - | IPO Subscribe | - | -% |
Senores Pharmaceuticals Corporate Filings
Senores Pharmaceuticals BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 30 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Senores Pharmaceuticals Limited has informed the exchange regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 2026 | |
| 29 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 | |
| 29 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants, For The Quarter Ended On September 30, 2026 | Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants for quarter ended on September 30, 2026 | |
| 29 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On September 30, 2026 | Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026 | |
| 29 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report | Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 |
Senores Pharmaceuticals Documents
Senores Pharmaceuticals Earnings Call
Senores Pharmaceuticals earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 29 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
| 03 Aug 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 27 Jul 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
| 27 Jul 2026 | Senores Pharmaceuticals Results Earnings Call for Q1FY27 | AudioVideo |
| 19 May 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
Senores Pharmaceuticals Annual Reports
Senores Pharmaceuticals financials, including annual results, balance sheets, and cash flow statements.
Senores Pharmaceuticals Investor Presentations
Senores Pharmaceuticals investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 29 Oct 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 27 Jul 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 14 May 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 20 Jan 2026 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 15 Dec 2025 | Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
Senores Pharmaceuticals - Company Profile
Senores Pharmaceuticals Management Structure
Senores Pharmaceuticals management structure with salaries, total experience, and qualifications.
Senores Pharmaceuticals Board of Directors
Senores Pharmaceuticals Board of directors with salaries, total experience, and qualifications.
Website: www.senorespharma.com
About the company - Business Profile
Senores Pharmaceuticals Limited is a research-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex pharmaceutical products. The company focuses on specialty and underpenetrated therapeutic areas, maintaining a significant presence in regulated markets such as the United States, Canada, and the United Kingdom, as well as several emerging markets. Its business model integrates in-house research and development with advanced manufacturing capabilities to deliver niche generic formulations.
Key Points
- Key Facts: Senores Pharmaceuticals Limited was incorporated in 2017 and is headquartered in Ahmedabad, Gujarat. The company is listed on both the BSE (Scrip Code: 544319) and the NSE (Symbol: SENORES).
- Operations and Resources: The company operates through several key facilities and subsidiaries. It possesses a USFDA and DEA-approved formulation facility in Atlanta, USA, operated through its subsidiary Havix Group Inc. In India, it operates a WHO-GMP approved facility at Chhatral through its subsidiary Ratnatris Pharmaceuticals.
- Ownership: The company is lead by Promoter and Managing Director Swapnil Jatinbhai Shah. Significant subsidiaries include Senores Pharmaceuticals Inc. (100% ownership), Havix Group Inc. (73.28% stake), and Ratnatris Pharmaceuticals Pvt. Ltd. (69% stake).
- Market Significance: Senores serves over 40 countries. It has a robust portfolio in regulated markets with 32 commercialized products, 81 approved ANDAs, and a pipeline of 70 products, including 50 Competitive Generic Therapy (CGT) opportunities.
- Business Model: The company utilizes multiple business models including Product-to-Product (P2P), Contract Development and Manufacturing Organization (CDMO), and distributor-led models for its own brands. It specializes in identifying and developing specialty, complex generics that are under-served in the market.
- Revenue and Financial Performance (FY2024-25):
- Total Income: Rs 418 crore.
- EBITDA: Rs 109 crore with a margin of 27.4%.
- Profit Before Tax (PBT): Rs 70.6 crore (16.9% margin).
- Geographical Revenue Mix (H1FY26): Regulated Markets (66%), Emerging Markets (20%), and Others (14%).
- Key Products and Innovation: The company’s portfolio includes diverse therapeutic areas such as oncology and complex generics. Notable products in the pipeline or registration phase include Sugammadex, Ferric Carboxymaltose, Tofacitinib, and Apixaban.
- Strategic Initiatives: Current focus areas include strengthening the research foundation, expanding global presence, and accelerating access to high-quality affordable solutions. The company is actively pursuing growth in the US market through its Atlanta facility and expanding its footprint in LATAM, Africa, and Southeast Asia.